Clinical Trials Logo

Clinical Trial Summary

COPD is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases. COPD is third leading cause of death worldwide. "Ideal cardiovascular health," a set of factors, including several directly along the causal pathway of transitions from health to disease, that protect against the development of cardiac disease. Working definition of respiratory health are the dual concepts of pulmonary reserve, as reflected by peak lung function in young adulthood, and susceptibility, as reflected by risk for future accelerated decline in lung function after the attainment of this peak. There is relationship between physical activity, disease severity, health status and prognosis in patients with COPD. Common pulmonary function tests include spirometry, lung volumes, and diffusing capacity for carbon monoxide (DLCO). Spirometry assesses airflow limitation. Diffusing capacity for carbon monoxide provides information on the health of alveolar-capillary membrane. This study will be cross-sectional correlational study. It will find correlation between person's physical activity and respiratory health. IPAQ and 6MIN walk test will be used as measuring tools of physical activity and FEV1 and TLV for estimating respiratory health. Spirometer will be used to measure respiratory health. Data will be collected from different hospital settings and analysed using SPSS software. All ethical considerations will be followed.


Clinical Trial Description

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous and multisystemic disease with progressive increasing morbidity and mortality. Chronic obstructive pulmonary disease (COPD) is a deteriorating respiratory disease with some extrapulmonary effects that contribute to disease severity in patient. The etiology, in general, involves exposure to external noxious particles or gases. In the Western world this is particularly a result of (cigarette) smoking and in the non-Western world it is mainly a result of indoor cooking. COPD pathology is driven by chronic inflammation, which continues to be observed after stopping smoking, even after ⩾1 year. The combination of the exposure and inflammation leads to lung tissue damage, resulting in remodeling of the lung.Global Burden of Disease programme in 2010 identified chronic obstructive pulmonary disease (COPD) as the third leading cause of death worldwide up from 4th in 1990. This high mortality due to COPD is caused due to smoking and rapidly aging population. China alone contributed to about one-third (0.9million/year) of all deaths from COPD worldwide. Within China, the prevalence of COPD varies substantially by region and death rates attributed to COPD are twofold greater in South-West compared with North-East regions for reasons that are not fully understood. Physical activity in terms of body movements, walking time and standing time has been shown to be reduced in patients with severe COPD. However, it is currently unknown at which clinical stage of the disease limitations of physical activity are first displayed. Furthermore, the relationships between physical activity and clinical characteristics reflecting the disease severity, such as the degree of airway obstruction, distance walked in 6 min, self-reported grade of dyspnea and clinical stages of COPD, need to be investigated as, to date, data are inconclusive or have never been evaluated. For example, some studies have found substantial correlations between airway obstruction and physical activity, while others found no or only loose relationships. Previous studies indicate that the 6-min walking distance (6MWD) might best reflect physical activity, while a recent study found airway obstruction to correlate with physical activity better than 6MWD. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05110755
Study type Observational
Source Riphah International University
Contact
Status Completed
Phase
Start date April 1, 2021
Completion date December 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy